You are here: Home
Categories

denosumab:

1. Treatment of Castration Resistant Prostate Cancer
... of the RANKL system represents an evolving bone-targeted strategy. Denosumab, a fully human monoclonal antibody against RANKL has been approved for the prevention of skeletal-related events in patients ...
2. Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases, by Jipan Xie, MD, PhD
BERKELEY, CA (UroToday.com) - Commentary on the Cost-Effectiveness of Denosumab vs. Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases ...
3. Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy, "Beyond the Abstract," by Claude C. Schulman MD, PhD, et al.
BERKELEY, CA (UroToday.com) - Many patients with prostate cancer (PCa) currently receive long-term androgen deprivation therapy (ADT) for advanced disease or as an adjuvant to radiotherapy for high-risk ...